Brought to you by 
AbbVie, Calico aim to advance cancer, neuro drugs through ten-year R&D pact; later extend deal
27 Jul 2021
Executive Summary
In a collaboration that could run as long as ten years, AbbVie Inc., and biotech start-up Calico Life Sciences LLC (diseases related to aging) aim to create a leading San Francisco R&D facility focused on age-related diseases--particularly neurodegeneration and cancer--to discover and accelerate development of new therapies.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AbbVie, Calico aim to advance cancer, neuro drugs through ten-year R&D pact; later extend deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice